This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for Adicet Bio (ACET) This Earnings Season?
by Zacks Equity Research
Adicet Bio (ACET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Adicet Bio, Inc. (ACET) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adicet Bio, Inc. (ACET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Adicet Bio (ACET)
by Zacks Equity Research
Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Strong Sell Stocks for May 28th
by Zacks Equity Research
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher
by Zacks Equity Research
Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.
New Strong Sell Stocks for April 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for April 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for March 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for November 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Weakness Seen in Aceto Corporation (ACET) Estimates: Should You Stay Away?
by Zacks Equity Research
Aceto Corporation (ACET) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
by Zacks Equity Research
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
5 Stocks to Bet on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Should You Get Rid of INC Research (INCR) Now?
by Zacks Equity Research
INC Research (INCR) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Investing Podcast Highlights: Snapchat, Israeli Tech Companies, Movie Stocks, and More
by Ryan McQueeney
Investing Podcast Highlights: Snapchat, Israeli Tech Companies, Movie Stocks, and More
Top Ranked Value Stocks to Buy for March 6th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, March 6th:
Should You Get Rid of Ensign Group (ENSG) Now?
by Zacks Equity Research
Ensign Group (ENSG) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Top Ranked Value Stocks to Buy for March 2nd
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, March 2nd:
3 Value Stocks on Sale
by Tracey Ryniec
Do you have the guts to buy a stock that has sold off when the market is hitting new highs?
Top Ranked Value Stocks to Buy for February 28th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, February 28th:
Top Ranked Value Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, February 27th: